HOME ·

BAIYUNSHAN PH

BAIYUNSHAN PH (00874.HK): Guangzhou Pharmaceutical Disposes Accounts Receivable of Approximately RMB 149 Million
Tags：
BAIYUNSHAN PH00874.HKDisposal of Receivables
2026-08-28
BAIYUNSHAN PH (00874.HK): Subsidiary's Norepinephrine Bitartrate Injection Passes Generic Drug Consistency Evaluation
Tags：
BAIYUNSHAN PH00874.HKR&D Progress
2026-08-24
BAIYUNSHAN PH (00874.HK): subsidiary's Citicoline Sodium Injection obtains supplementary drug application approval and consistency evaluation
Tags：
BAIYUNSHAN PH00874.HKPharmaceutical
2026-08-19
BAIYUNSHAN PH (00874.HK): subsidiary's Cefazolin Sodium for Injection obtains Macao pharmaceutical registration certificate, to be sold in Macao under authorization
Tags：
BAIYUNSHAN PH00874.HKDrug Registration Certificate
2026-08-17
BAIYUNSHAN PH(00874.HK): Subsidiary Zhongyi Pharmaceutical Obtains Revised Drug Production Licence with Removal of Production Site and Change of Production Person‑in‑Charge
Tags：
BAIYUNSHAN PH00874.HKDrug Production Licence
2026-08-04
BAIYUNSHAN PH (00874.HK): Cefalexin Capsules Obtain Proprietary Medicine Registration Certificate from Macao Drug Administration
Tags：
BAIYUNSHAN PH00874.HKdrug registration application
2026-07-20
BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
Tags：
BAIYUNSHAN PH00874.HKNMPA Approval
2026-07-09
BAIYUNSHAN PH(00874.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at CNY 1.78 billion, YoY decrease of 2.06%
Tags：
BAIYUNSHAN PH00874.HKfinancials
2026-04-27